Imcyse is a clinical-stage biopharmaceutical company focused on advancing the development of specific immunotherapies for severe autoimmune diseases. The company's unique ImotopeTM platform aims to address a wide range of immunologic diseases.

Imcyse

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Metric
Company Name	Imcyse	LégiaPark	Oxurion NV
Symbol			OXUR
MSH ID	COM:IMCYSE	BE:LEGIAPARK	COM:OXURION
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Commercial & Professional Services	Healthcare
Industry	Biopharmaceuticals	Life Sciences	Biotechnology
Country	BE	BE	BE
Stage
Employee Count			20
Website	imcyse.com	legiapark.be	oxurion.com
LinkedIn		l%C3%A9giapark
Founders

Metric
Market Cap			2.59M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			277.79K
Revenue (LTM)
Revenue (NTM)
Gross Profit			109.85K
EBITDA			-14.24M
Operating Income			-12.79M
Net Income			-20.04M
EPS			-0.01
Diluted EPS			-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-0.16
Operating Profit Margin			-32.84
EBITDA Margin			-51.27
Net Profit Margin			-54.03
Return on Equity			4.21
Return on Assets			-2.35
Return on Capital Employed			2.47

COM:IMCYSE

Imcyse

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-0.00
P/B Ratio			-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			15.36
EV Multiple			1.55

Metric
Days Sales Outstanding
Days Payables Outstanding			3.59K
Days Inventory Outstanding			0.45
Operating Cycle			3.72K
Cash Conversion Cycle			479.87
Asset Turnover			0.08

Metric
Operating Cash Flow			-10.31M
Free Cash Flow			-10.32M
Cash Flow to Debt			-0.39
Operating Cash Flow/Sales			-17.83
Free Cash Flow Yield			-11.06

Metric
Cash & Equivalents			1.72M
Accounts Receivable			2.83M
Inventory			135.20K
Goodwill
Debt to Capitalization			6.89
Debt to Assets			0.67
Current Ratio			0.58
Quick Ratio			0.40

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			1.57
R&D to Revenue			26.87
SG&A to Revenue			7.45